Epic Sciences, a private biotech company that develops cancer diagnostics, announced the appointment of According to a release, Dr. Prahalad was formerly vice president of Corporate Strategy at
"Dr. Prahalad has extensive experience in creating and leading global strategies for life science research tools and diagnostics as well as building innovative teams and forging productive partnerships," said
Epic noted it develops new diagnostic tests that isolate and characterize circulating tumor cells (CTCs) to assess the aggressiveness of a patient's cancer and provide physicians tools to personalize and monitor treatments. CTCs are cells that escape from solid tumors and enter the bloodstream. A blood test that can accurately count CTCs in a patient's blood and profile biomarkers within those CTCs is easy to conduct frequently and can give essential, real-time information that enables the tailoring of treatments to a patient's specific cancer type.
"The team at Epic has quickly proven and developed a complete technology platform that can detect, quantify and molecularly characterize rare, circulating tumor cells. They have also developed significant partnerships with pharmaceutical companies, leading academic labs and research institutions to advance Epic's technology for companion diagnostics and new cancer detection tests," said Dr. Prahalad, president and CEO of Epic Sciences. "I look forward to working with the team and our partners to build a robust pipeline of new diagnostic tests that improve cancer detection and treatment for patients globally."
Dr. Prahalad was with
Portfolios of note and relevance to Epic included Molecular Probes, transfection (Lipofectamine), custom primers and research antibodies in addition to
((Comments on this story may be sent to email@example.com))
Epic Sciences, a private biotech company that develops cancer diagnostics, announced the appointment of
According to a release, Dr. Prahalad was formerly vice president of Corporate Strategy at